• Caifeng Zhang, Dongling Yan, Xiaojing Wang, and Dianchen Cheng.
• Department of Gynaecology, Lanzhou Maternal and Child Health Hospital, Gansu, China.
• Medicine (Baltimore). 2023 Jan 13; 102 (2): e32312e32312.

BackgroundPolycystic ovary syndrome (PCOS) is a frequent endocrine disorder in women, it is the principal cause of infertility and amenorrhea. Due to its high recurrence rate, poor prognosis and serious complications, more works on the research of PCOS are needed. Therefore, we performed a protocol for systematic review and meta-analysis to investigate the efficacy and safety of glucagon-like peptide-1 receptor agonists on ovarian dysfunction in PCOS.MethodsThis study protocol has been registered in the PROSPERO and the registration number is CRD42020188247. The procedure of this protocol will be conducted according to the Preferred Reporting Item for Systematic Review and Meta-analysis Protocols guidance. A comprehensive search of several databases from 1966 to November 2022 will be conducted. The databases includes Ovid Medline In-Process & Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and PubMed. The risk of bias of the included studies will be assessed using the Cochrane tool of risk of bias. All statistical analyses will be conducted using the software program Review Manager version 5.3.ResultsThe results of this systematic review will be published in a peer-reviewed journal.ConclusionThis systematic review will provide evidence to judge whether glucagon-like peptide-1 receptor agonist is superior to metformin in patients with PCOS.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

25 keywords...

hide…